key: cord-0790510-uodugz0d authors: SOURIS, M.; TSHILOLO, L.; PARZY, D.; KAMGAING, R.; MBONGI, D.; PHOBA, B.; TSHILOLO, M.-A.; MBUNGU, R.; MORAND, P.; GONZALEZ, J.-P. title: Pre-pandemic SARS-CoV-2 potential natural immunity among population of the Democratic Republic of Congo date: 2021-05-01 journal: nan DOI: 10.1101/2021.04.28.21256243 sha: fb946772811f6de0f39ecefff249a20e244fce10 doc_id: 790510 cord_uid: uodugz0d More than a year after the emergence of COVID-19, significant regional differences in terms of morbidity persist, showing lower incidence rates in sub-Saharan Africa, Southeast Asia, and Oceania. Like SARS-CoV-1 and MERS viruses, SARS-CoV-2 is monophyletically positioned with parental species of chiropteran coronavirus. Furthermore, we observe that the spatial distribution of several targeted bat species (i.e., Coronavirus species hosts) overlaps the distribution of countries with low COVID-19 incidence. The work presented here aims to test the presence of natural immunity among population with a low COVD-19 prevalence, potentially due to a previous exposure to coronavirus antigens of a virus close related to SARS-CoV-2. To identify such pre-existing immunity, an ELISA serological test was used to detect IgG antibodies targeting main SARS-CoV-2 proteins including: the N-protein, the Spike 1 (S1) protein, the receptor binding domain (RBD) of the S1 protein, the N-terminal domain (NTD) of the S1 protein, and the S2 protein. A total of 574 sera samples collected before 2019 in the population of the Democratic Republic of Congo (DRC) were tested). 189 control sera from blood donors in France were used as control samples. The results showed a statistically significant difference between the DRC samples and control samples for all antigens (N, S1, S2, NTD) except for RBD. The percentage of positive samples presenting reactive antibodies for S1 antigen was respectively of 19.2% for RDC versus 2.11% for the control, and of 9.3% versus 1.6% for the S2 antigen. In conclusion, our data showed that the study population has been potentially exposed to a SARS-CoV-2-like virus antigen before the pandemic in the Central African sub-region. Therefore, it is quite legitimate to think that this prior immunity may be protective and responsible for the observed low prevalence of COVID-19. Moreover, we can assume that this not yet identified SARS-CoV-2-like could be associated to a chiropteran species in close contact with the studied population. In order to confirm the presence of SARS-CoV-2-like virus antibodies and ultimately identify the neutralizing potential for the detected antibodies, our study is underway in other African and Asian countries, where the COVID-19 prevalence is limited. In conclusion, our data showed that the study population has been potentially exposed to a 48 SARS-CoV-2-like virus antigen before the pandemic in the Central African sub-region. 49 Therefore, it is quite legitimate to think that this prior immunity may be protective and 50 responsible for the observed low prevalence of COVID-19. Moreover, we can assume that 51 this not yet identified SARS-CoV-2-like could be associated to a chiropteran species in close 52 contact with the studied population. In order to confirm the presence of SARS-CoV-2-like 53 virus antibodies and ultimately identify the neutralizing potential for the detected antibodies, 54 our study is underway in other African and Asian countries, where the COVID-19 prevalence 55 is limited. 56 57 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 1, 2021. COVID-19 morbidity in the world. More than a year after the emergence of COVID-19, 59 significant regional differences persist, showing the lowest incidence rates in sub-Saharan 60 Africa, Southeast Asia, and Oceania. This trend was observed at the onset of the epidemic 61 and has been confirmed during subsequent waves [WHO 2021] . Many hypotheses have been proposed to explain this situation, including among others: the 66 morbidity and mortality counts are likely to be underestimated in some low-and middle-67 income countries due to limited epidemiological surveillance and/or public health screening 68 activity; the population of sub-Saharan Africa is younger, with only 2.3% of the population 69 over 65 years of age (whereas people over 65 years of age account for more than three-70 quarters of the deaths related to COVID-19 in Europe, where this population represents more 71 than 20% of the population); more rural living conditions may reduce the spread of the 72 disease; climatic and environmental conditions unfavorable to the virus and its spread; 73 and/or, the presence of a natural immunity innate (nonspecific) or secondary due to previous 74 contact with a coronavirus close to SARS-CoV-2 and sharing common antigenic profiles. 75 The present work aims to test this last hypothesis. 76 Coronavirus and bats. SARS-CoV-2 virus pertains to the Betacoronavirus genus, which 77 includes numerous virus species of Chiropterans. Chiropteran species are also supposed hosts 78 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. [Hu 2017 ]. Globally, it can be observed that the spatial 83 distribution of fruit bats matches the spatial distribution of countries with lower symptomatic 84 circulation of COVID-19, especially in rural populations (Fig. 2) . Ecology and behavior of 85 bats, especially fruit bats (e.g.: mass frequentation of fruit orchards, roosting trees close to 86 dwelling) may have favored the direct or indirect contact with humans. Such type of 87 antigenic relationship and acquisition of natural immunity without morbidity, have already 88 been observed with several viruses, including filoviruses and flaviviruses [Gonzalez 2000 ] 89 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 1, 2021. ; https://doi.org/10.1101/2021.04.28.21256243 doi: medRxiv preprint during the externalization of viral particles from the infected cell and is an internal protein of 102 the virus [Wang 2020]. The N protein appears more conserved across Betacoronavirus 103 species than the S protein, while the RBD appears more conserved within the S1 unit. From 104 the point of view of protection (i.e., neutralizing antibodies), there is a strong correlation 105 between the levels of RBD antibodies and the neutralizing antibodies to SARS-CoV-2 in 106 humans [Premkumar 2020 ]. Also, SARS-CoV-2 genome is closely related to SARS-CoV-1 107 (79.6% genomic sequence identity), several antibodies covering all structural proteins of 108 SARS-CoV-1 (spike, membrane, nucleocapsid, envelope) have been identified and 109 extensively studied showing cross-reactivity with SARS-CoV-2, as well as partial cross-110 neutralization of spike antibodies [Bates 2020 ]. Moreover, sera from SARS-CoV-1 111 convalescent or S1 CoV-specific animal antibodies can neutralize SARS-CoV-1 infection by 112 reducing S protein-mediated SARS-CoV-1 entry [He 2006 ]. Finally, SARS-CoV-1 and 113 MERS-CoV show that many fragments (S1-NTD, RBD, S2) of S protein are targets for 114 neutralizing antibody production [He 2006 ] [Jiang 2020 ]. 115 The objective of this present study was to identify a pre-existing natural humoral anti-SARS-117 CoV-2 immunity among population of African countries from sera repository collected 118 several months before the COVID-19 epidemic started. Our work aimed to test the hypothesis 119 of a previous exposure to a SARS-CoV-2 like antigens. We present here our first results, 120 obtained from sera samples collected before January 2020 from people living in the 121 Democratic Republic of Congo (DRC). 122 Antibody detection. The INNOBIOCHIPS ELISA serological test used, detects the IgG 124 antibodies targeting the N protein, the S1 protein, the RBD domain of the S1 protein, the 125 NTD domain of the S1 protein and the S2 protein. Etablissement Français du Sang) and tested negative for SARS-CoV-2 by PCR. These sera 133 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 1, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 1, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Antibodies against all five SARS-CoV-2 antigens were detected in the pre-COVID samples, 180 with differential optical density mean value for DRC samples significantly higher than for the 181 control samples, except for RBD antigen The S1 antigen shows the highest percentage of 182 positives: 19.2% for DRC samples versus 2.11% for the control samples. The S2 antigen also 183 shows high rate: 9.3% for DRC samples vs 1.6% for control samples ( Table 2 ). The Hotelling 184 test confirmed a high significant difference (T2 = 35, F = 7, p-value=2.2*10 -6 ) when all 185 antigens were considered together. 186 Table 2 . Democratic Republic of Congo study samples values (differential optical density). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 1, 2021. ; https://doi.org/10.1101/2021.04.28.21256243 doi: medRxiv preprint HCoV-229E) and confirms that the identified antibodies react precisely against the SARS-212 Cov-2 proteins. The novelty of our finding is that a stronger cross-reactivity in central 213 African regions may come from exposure, not to HCoVs, but to other animal coronaviruses 214 or more specifically ones associated to chiropteran. Also, several betacoronaviruses have 215 been found in horseshoe bats, as well as specific antibody response to these viruses in fruit 216 bats in Africa [Nziza 2020 ] [Müller 2007] . 217 Based on what we observed that cross-reactivity to S1 and S2, considered specific to SARS-218 CoV-2, was stronger than for the N protein, considered common to beta-coronaviruses, 219 therefore, it can be assumed that cross-reactivity to S1 and S2 must have been induced by a 220 virus similar -by this spike epitopes -to SARS-CoV-2, rather than by other known human 221 betacoronaviruses. Indeed, The S1 subunit is the least conserved and cross-reactivity cannot 222 be explained by exposure to the known Human CoVs while the N and S2 proteins are the 223 most conserved. Moreover, such cross-reactivity with S1 does not quantitatively reproduced 224 the S1-RBD or S1-NTD data. These apparent discrepancies can be explained by a variation 225 of antibodies affinities to these epitopes due to the structure of the spike or due to a change in 226 their amino acid sequence. Eventually a more consistent response with S1 could be the fact of 227 a non-tested here CTD protein [Van Elslande 2020]. Altogether such apparent discrepancy of 228 antibody response is in favor of an S1 belonging to a Sars-Cov2-like, while all sequence of 229 the antigens included in the commercial ELISA (INNOBIOCHIPS) were entirely based on 230 the reference SARS-CoV-2 strain. It is also important to note that S and N protein sequences 231 are equally divergent among coronaviruses while the S2 subunit is better conserved than the 232 N protein. 233 We are aware of the limitations of this somewhat pioneering study. The next step is to 234 conduct sensitive investigations of populations potentially exposed to wild animals and to 235 perform back-to-back with the present ELISA test, an essential SARS-Cov-2 neutralization 236 assays to confirm the surprisingly high S1 cross-reactivity and the potential of the antibody to 237 protect against SARS-CoV-2. In addition, most of the samples tested came from rural areas 238 of Central Congo (e.g.: Kimpese of Lower Congo, Kisantu of Western Congo). Furthermore, 239 if it is true that background reactivity in SARS-CoV-2 serological tests is higher, especially 240 in African populations, this may be due not only to widespread circulation/exposure of/to 241 Sarbecoviruses (alias Betacoronavirus) of animals or chiropterans, but to a potential increased 242 cross-reactivity induced by other microorganisms (e.g., malaria, tuberculosis, etc.) as 243 previously observed [Ng 2020 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 1, 2021. ; https://doi.org/10.1101/2021.04.28.21256243 doi: medRxiv preprint CONCLUSION 245 In conclusion, our study strongly suggests that a SARS-CoV-2-like virus circulated in the 246 Central African sub-region before the pandemic, inducing a cross immunity and eventual 247 cross-protection in the local population. Given the now well-established phylogeny of 248 Betacoronavirus, it is likely that this not yet identified virus could be associated with 249 chiropteran species. Our study is underway in other African and Asian countries, as well as 250 evaluating the neutralizing potential of these pre-pandemic SARS-CoV-2 antibodies. 251 252 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 1, 2021. ; https://doi.org/10.1101/2021.04.28.21256243 doi: medRxiv preprint Cross-254 reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2 High prevalence of both 257 humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon SARS-CoV-2-reactive T cells in healthy 260 donors and patients with COVID-19 Marburg virus antibody prevalence in selected populations of the Central African Republic Cross-neutralization of human and palm civet severe acute respiratory 267 syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein Discovery of a rich gene pool of bat SARS-270 related coronaviruses provides new insights into the origin of SARS coronavirus A novel SARS-CoV-2 related coronavirus in 273 bats from Cambodia Neutralizing Antibodies against SARS-CoV-2 and 279 Other Human Coronaviruses IFCC interim guidelines on serological testing of 282 antibodies against SARS-CoV-2 Structure of the SARS-CoV-2 spike receptor-binding 286 domain bound to the ACE2 receptor SARS-CoV-2-specific T cell 288 immunity in cases of COVID-19 and SARS, and uninfected controls Bats are natural reservoirs of SARS-like coronaviruses Coronaviruses closely related to the pandemic virus 293 discovered in Japan and Cambodia Selective and cross-reactive SARS-CoV-2 T cell epitopes in 295 unexposed humans Coronavirus antibodies in African 297 bat species Preexisting and de novo humoral 299 immunity to SARS-CoV-2 in humans The receptor binding 304 domain of the viral spike protein is an immunodominant and highly specific target of 305 antibodies in SARS-CoV-2 patients All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted May 1, 2021. ; https://doi.org/10.1101/2021.04.28.21256243 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted May 1, 2021. ; https://doi.org/10.1101/2021.04.28.21256243 doi: medRxiv preprint